Somasekar Seshagiri

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. pmc Sequencing and analysis of a South Asian-Indian personal genome
    Ravi Gupta
    SciGenom Labs Pvt Ltd, Kakkanad, Cochin, Kerala, India
    BMC Genomics 13:440. 2012
  2. doi request reprint The burden of faulty proofreading in colon cancer
    Somasekar Seshagiri
    Genentech Inc, Department of Molecular Biology, South San Francisco, California, USA
    Nat Genet 45:121-2. 2013
  3. pmc Recurrent R-spondin fusions in colon cancer
    Somasekar Seshagiri
    Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 488:660-4. 2012
  4. doi request reprint Oncogenic ERBB3 mutations in human cancers
    Bijay S Jaiswal
    Department of Molecular Biology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Cell 23:603-17. 2013
  5. doi request reprint Diverse somatic mutation patterns and pathway alterations in human cancers
    Zhengyan Kan
    Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 466:869-73. 2010
  6. pmc Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers
    Chaitali Parikh
    Department of Molecular Biology, Genentech Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 109:19368-73. 2012
  7. doi request reprint RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    Georgia Hatzivassiliou
    Genentech, South San Francisco, California 94080, USA
    Nature 464:431-5. 2010
  8. pmc Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation
    Bijay S Jaiswal
    Department of Molecular Biology, Genentech Inc, South San Francisco, CA 94080, USA
    Cancer Cell 16:463-74. 2009
  9. pmc Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors
    Bijay S Jaiswal
    Department of Molecular Biology, Genentech Inc, South San Francisco, California, United States of America
    PLoS ONE 4:e5717. 2009
  10. doi request reprint Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression
    Klaus P Hoeflich
    Department of Cancer Signaling and Translational Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 69:3042-51. 2009

Collaborators

Detail Information

Publications33

  1. pmc Sequencing and analysis of a South Asian-Indian personal genome
    Ravi Gupta
    SciGenom Labs Pvt Ltd, Kakkanad, Cochin, Kerala, India
    BMC Genomics 13:440. 2012
    ..In this study we have sequenced and analyzed the genome of a South Asian Indian female (SAIF) from the Indian state of Kerala...
  2. doi request reprint The burden of faulty proofreading in colon cancer
    Somasekar Seshagiri
    Genentech Inc, Department of Molecular Biology, South San Francisco, California, USA
    Nat Genet 45:121-2. 2013
    ..A new study reports the identification of germline CRC risk variants that adversely affect the proofreading function of DNA polymerases encoded by POLE and POLD1...
  3. pmc Recurrent R-spondin fusions in colon cancer
    Somasekar Seshagiri
    Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 488:660-4. 2012
    ..The R-spondin gene fusions and several other gene mutations identified in this study provide new potential opportunities for therapeutic intervention in colon cancer...
  4. doi request reprint Oncogenic ERBB3 mutations in human cancers
    Bijay S Jaiswal
    Department of Molecular Biology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Cell 23:603-17. 2013
    ..Furthermore, we found that anti-ERBB antibodies and small molecule inhibitors effectively blocked mutant ERBB3-mediated oncogenic signaling and disease progression in vivo...
  5. doi request reprint Diverse somatic mutation patterns and pathway alterations in human cancers
    Zhengyan Kan
    Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 466:869-73. 2010
    ..Our study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets...
  6. pmc Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers
    Chaitali Parikh
    Department of Molecular Biology, Genentech Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 109:19368-73. 2012
    ..These results have important implications for therapeutic intervention in patients with AKT mutations at the PH-KD interface...
  7. doi request reprint RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    Georgia Hatzivassiliou
    Genentech, South San Francisco, California 94080, USA
    Nature 464:431-5. 2010
    ..Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors...
  8. pmc Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation
    Bijay S Jaiswal
    Department of Molecular Biology, Genentech Inc, South San Francisco, CA 94080, USA
    Cancer Cell 16:463-74. 2009
    ..The p85alpha mutants promote cell survival, AKT activation, anchorage-independent cell growth, and oncogenesis in a p110-dependent manner...
  9. pmc Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors
    Bijay S Jaiswal
    Department of Molecular Biology, Genentech Inc, South San Francisco, California, United States of America
    PLoS ONE 4:e5717. 2009
    ..Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone or in combination to target RAS-driven tumors...
  10. doi request reprint Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression
    Klaus P Hoeflich
    Department of Cancer Signaling and Translational Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    Cancer Res 69:3042-51. 2009
    ..Taken together, these studies increase our understanding of the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition and have implications for therapeutic intervention in the clinic...
  11. pmc Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples
    Serban Nacu
    Department of Bioinformatics and Molecular Biology, Genentech, Inc, South San Francisco, California 94080, USA
    BMC Med Genomics 4:11. 2011
    ..Deep transcriptional sequencing (RNA-Seq) now makes it possible to study the occurrence and expression levels of TICs in individual samples across the genome...
  12. doi request reprint PPM1H is a p27 phosphatase implicated in trastuzumab resistance
    Si Tuen Lee-Hoeflich
    Genentech Research and Early Development, South San Francisco, California 94080, USA
    Cancer Discov 1:326-37. 2011
    ..Furthermore, low PPM1H expression may identify a subset of HER2-positive tumors that are harder to treat...
  13. doi request reprint Oncogenic activating mutations are associated with local copy gain
    Barmak Modrek
    Department of Bioinformatics, Genentech, Inc, South San Francisco, California, USA
    Mol Cancer Res 7:1244-52. 2009
    ..However, KRAS activating mutations in colorectal cancer were not associated with copy gains. Future work is warranted to clarify the relationship among the different mechanisms of oncogene activation...
  14. doi request reprint Inducible BRAF suppression models for melanoma tumorigenesis
    Klaus P Hoeflich
    Genentech Inc, Department of Molecular Biology, South San Francisco, CA, USA
    Methods Enzymol 439:25-38. 2008
    ....
  15. pmc The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients
    Zhaoshi Jiang
    Department of Bioinformatics and Computational Biology, Genentech Inc, South San Francisco, California 94080, USA
    Genome Res 22:593-601. 2012
    ..Thus, we report the most comprehensive characterization of HBV integration in hepatocellular carcinoma patients. Such widespread random viral integration will likely increase carcinogenic opportunities in HBV-infected individuals...
  16. doi request reprint The mutation spectrum revealed by paired genome sequences from a lung cancer patient
    William Lee
    Department of Bioinformatics and Computational Biology, Genentech Inc, South San Francisco, California 94080, USA
    Nature 465:473-7. 2010
    ..We present a comprehensive view of somatic alterations in a single lung tumour, and provide the first evidence, to our knowledge, of distinct selective pressures present within the tumour environment...
  17. ncbi request reprint Somatic mutations lead to an oncogenic deletion of met in lung cancer
    Monica Kong-Beltran
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94114, USA
    Cancer Res 66:283-9. 2006
    ..These results support a critical role for Met in lung cancer and somatic mutation-driven splicing of an oncogene that leads to a different mechanism for tyrosine kinase activation through altered receptor down-regulation in human cancer...
  18. doi request reprint Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma
    Robert L Yauch
    Genentech, South San Francisco, CA 94080, USA
    Science 326:572-4. 2009
    ..These findings show that acquired mutations in a serpentine receptor with features of a G protein-coupled receptor can serve as a mechanism of drug resistance in human cancer...
  19. doi request reprint Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
    Ingrid E Wertz
    Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
    Nature 471:110-4. 2011
    ..Our findings suggest that profiling the FBW7 and MCL1 status of tumours, in terms of protein levels, messenger RNA levels and genetic status, could be useful to predict the response of patients to antitubulin chemotherapeutics...
  20. doi request reprint Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients
    Sara A Hurvitz
    University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 18:3478-86. 2012
    ..This study aimed to determine whether high-affinity SNPs are associated with disease-free survival (DFS) among patients with HER2-positive nonmetastatic breast cancer...
  21. pmc pHUSH: a single vector system for conditional gene expression
    Daniel C Gray
    Department of Molecular Biology, Genentech Inc, South San Francisco, California, USA
    BMC Biotechnol 7:61. 2007
    ..We have therefore developed pHUSH, an inducible expression system that allows regulated expression of shRNA, miRNA or cDNA cassettes on a single viral vector...
  22. ncbi request reprint Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection
    Brock A Peters
    Department of Molecular Biology, Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Methods 4:713-5. 2007
    ..Our results showed that MRD is a robust and cost-effective alternative to Sanger sequencing for identifying somatic mutations in human tumors...
  23. pmc A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis
    Nicholas Dompe
    Department of Molecular Biology, Genentech, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 108:E943-51. 2011
    ..Our findings highlight a mechanism by which cancer cells may evade apoptosis, and therefore provide insight in the search for new targets and functional biomarkers for this pathway...
  24. ncbi request reprint Loss of the tumor suppressor BAP1 causes myeloid transformation
    Anwesha Dey
    Department of Physiological Chemistry, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Science 337:1541-6. 2012
    ..A BAP1 catalytic mutation found in a MDS patient implies that BAP1 loss of function has similar consequences in mice and humans...
  25. doi request reprint CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma
    Bart Burington
    Department of Biostatistics, Genentech Inc, South San Francisco, CA 94080, USA
    Sci Transl Med 3:74ra22. 2011
    ..These data show that CD40 pathway activation status may be useful in predicting the antitumor activity of CD40-stimulating therapeutic drugs...
  26. ncbi request reprint Distinguishing cancer-associated missense mutations from common polymorphisms
    Joshua S Kaminker
    Department of Bioinformatics, Genentech, Inc, South San Francisco, California 94404, USA
    Cancer Res 67:465-73. 2007
    ..The data presented here show that this novel bioinformatics approach to classifying cancer-associated variants is robust and can be used for large-scale analyses...
  27. ncbi request reprint Oncogenic BRAF is required for tumor growth and maintenance in melanoma models
    Klaus P Hoeflich
    Department of Molecular Biology, Genentech Inc, 1 DNA Way MS224, South San Francisco, CA 94080, USA
    Cancer Res 66:999-1006. 2006
    ..Taken together, gain-of-function BRAF signaling is strongly associated with in vivo tumorigenicity, confirming BRAF as an important target for small-molecule and RNA interference-based therapeutics...
  28. pmc Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin
    Albert Lai
    David Geffen School of Medicine at theUniversity of California at Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 29:4482-90. 2011
    ..To determine how GBMs arising with IDH1(R132MUT) differ from other GBMs, we undertook a comprehensive comparison of patients presenting clinically with primary GBM as a function of IDH1(R132) mutation status...
  29. ncbi request reprint Regulation of ERK3/MAPK6 expression by BRAF
    Klaus P Hoeflich
    Department of Molecular Biology, Genentech, South San Francisco, CA 94080, USA
    Int J Oncol 29:839-49. 2006
    ..These results provide strong evidence for another mode by which BRAF can regulate the ERK protein kinase family and suggest ERK3 to be a potential pharmacodynamic marker for targeting BRAF signaling in melanoma...
  30. ncbi request reprint Estimation of baculovirus titer based on viable cell size
    Vasantharajan Janakiraman
    Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Protoc 1:2271-6. 2006
    ..The cell diameter change data were used to compute the virus titer using a statistical method called the method of moments that we have described previously...
  31. doi request reprint DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer
    Kim Walter
    Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 18:2360-73. 2012
    ..Here, we test the hypothesis that epithelial-like NSCLCs can be distinguished from mesenchymal-like NSCLCs on the basis of global DNA methylation patterns...
  32. ncbi request reprint ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage
    David Dornan
    Department of Physiological Chemistry, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Science 313:1122-6. 2006
    ..Furthermore, phosphorylation of COP1 on Ser(387) was required to permit p53 to become stabilized and to exert its tumor suppressor properties in response to DNA damage...
  33. ncbi request reprint Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
    Robert L Yauch
    Department of Molecular Diagnostics, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 11:8686-98. 2005
    ..These data support a potential role for EMT as a determinant of EGFR activity in NSCLC tumor cells and E-cadherin expression as a novel biomarker predicting clinical activity of the EGFR inhibitor erlotinib in NSCLC patients...